Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study

Clinical Therapeutics

Volumn 30, Issue 10, 2008, Pages 1806-1816

  Burge, Daniel J ^a   Bookbinder, Stephen A ^b   Kivitz, Alan J ^c   Fleischmann, Roy M ^d   Shu, Cathye ^e   Bannink, Jeannette ^a  

^a Trubion Pharmaceuticals   (United States)

^b Ocala Rheumatology Research Center   (United States)

^c Altoona Center for Clinical Research   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e PFIZER INC   (United States)

Author keywords

B cell depletion; immunopharmaceutical; pharmacodynamics; pharmacokinetics; rheumatoid arthritis

Indexed keywords

CD19 ANTIGEN; CD20 ANTIBODY; CORTICOSTEROID; METHOTREXATE; TRU 015; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; BACKACHE; BRONCHITIS; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; FATIGUE; FEMALE; FLOW CYTOMETRY; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; LYMPHOCYTE DEPLETION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PREMEDICATION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

ADULT; AGED; ANTIGENS, CD19; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; MIDDLE AGED; PEPTIDES; YOUNG ADULT;

EID: 56149114691     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.10.017     Document Type: Article

References (42)

1. Scott D.L., Smith C., and Kingsley G. Joint damage and disability in rheumatoid arthritis: An updated systematic review. Clin Exp Rheumatol 21 Suppl 31 (2003) S20-S27
2. Doran M.F., Pond G.R., Crowson C.S., et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 46 (2002) 625-631
3. Hazes J.M., and Silman A.J. Review of UK data on the rheumatic diseases-2. Rheumatoid arthritis. Br J Rheumatol 29 (1990) 310-312
4. Corbett M., Dalton S., Young A., et al. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 32 (1993) 717-723
5. The American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46 (2002) 328-346
6. Furst D.E., Breedveld F.C., Kalden J.R., et al. Updated consensus statement on biological agents, specifically tumour necrosis factor (alpha) (TNF[alpha]) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 64 Suppl 4 (2005) iv2-iv14
7. Choy E.H., Smith C., Doré C.J., and Scott D.L. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 44 (2005) 1414-1421
8. Remicade (infliximab) [prescribing information] (2008), Centocor, Inc, Malvern, Pa
9. Enbrel (etanercept) [prescribing Information] (2008), Amgen Inc, Thousand Oaks, Calif
10. HUMIRA (adalimumab) [prescribing information] (2008), Abbott Laboratories, North Chicago, Ill
11. Duclos M., Gossec L., Ruyssen-Witrand A., et al. Retention rates of TNF blockers in daily practice in 770 rheumatic patients. J Rheum 33 (2006) 2433-2439
12. Smith J.B., and Haynes M.K. Rheumatoid arthritis-a molecular understanding. Ann Intern Med 136 (2002) 908-922
13. Panayi G.S. The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics. Agents Actions Suppl 47 (1995) 1-21
14. Dörner T. Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells. J Rheumatol Suppl 77 (2006) 3-11
15. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
16. for the REFLEX Trial Group. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
17. for the DANCER Study Group. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
18. Edwards J.C., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 (2006) 394-403
19. Raderer M., Jäger G., Brugger S., et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 65 (2003) 306-310
20. Gong Q., Ou Q., Ye S., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 (2005) 817-826
21. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
22. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc?RIIIa gene. Blood 99 (2002) 754-758
23. van der Kolk L.E., Grillo-Lépez A.J., Baars J.W., et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115 (2001) 807-811
24. Barone D. Prolonged depletion of circulating B cells in cynomolgus monkeys after a single dose of TRU-015, a novel CD20 directed therapeutic. Ann Rheum Dis 64 Suppl III (2005) 159 Abstract
25. Barone D. TRU-015, a novel CD20-directed biologic therapy, demonstrates significant anti-tumor activity in human tumor xenograft models. J Clin Oncol 23 Suppl 16 (2005) 25-49 Abstract
26. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects (September 24, 2008). http://www.wma.net/e/policy/b3.htm Accessed
27. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the clas sification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
28. Hochberg M.C., Chang R.W., Dwosh I., et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35 (1992) 498-502
29. LeBien T.W., and Tedder T.F. B lymphocytes: How they develop and function. Blood 112 (2008) 1570-1580
30. Levesque M.C., and St Clair E.W. B celldirected therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 121 (2008) 13-21
31. DCTD, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0 [CTEP Web site] (August 9, 2006). http://ctep.cancer.gov Accessed
32. US Food and Drug Administration. Medical Dictionary for Regulatory Activities [MedDRA Web site] (October 3, 2008). http://www.meddramsso.com/MSSOWeb/index.htm Accessed
33. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24 (2006) 3121-3127
34. for the MabThera International Trial Group. Pfreundschuh M., Trümper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7 (2006) 379-391
35. Ding C., Foote S., and Jones G. B-cell-targeted therapy for systemic lupus erythematosus: An update. BioDrugs 22 (2008) 239-249
36. Lee R.W., and D'Cruz D.P. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Drugs 68 (2008) 747-770
37. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 141 (2008) 149-169
38. Dalakas M.C. Invited article: Inhibition of B cell functions: Implications for neurology. Neurology 70 (2008) 2252-2260
39. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93 (2004) 2645-2668
40. Burge D., Shu C., Martin R.W., et al. TRU-015, a Small Modular ImmunoPharmaceutical (SMIP) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Rheum 54 Suppl 9 (2006) S230
41. Barone D., Baum P., Ledbetter J., et al. Prolonged depletion of circulating B-cells in cynomolgus monkeys after a single dose of TRU-015, a novel CD20 directed therapeutic. Ann Rheum Dis 64 Suppl III (2005) 159
42. Bugelski P.J., and Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 6 (2004) 10-16